Shares of the German drug maker InflaRx (IFRX) fell sharply Wednesday after its lead drug failed to benefit patients with a debilitating skin disease in a clinical trial.

In the Phase 2 clinical trial, InflaRx tested four escalating doses of its injectable antibody drug called IFX-1 against a placebo in 179 patients with hidradenitis suppurativa, a painful skin disease characterized by inflamed hair follicles, mostly found in the armpits and groin. Involvement of the sweat glands within the follicles causes painful, pus-filled boils, nodules, and abscesses.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Adam,
    What’s the connection between Inflazrx and Moderna? Was it a spinoff, common ownership,? It doesn’t sound to me like the technology is particularly close?

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy